SEC Company Response from Tvardi Therapeutics, Inc. (TVRD) (CIK 0001346830) (TVRD) — Apr 2, 2019
Tvardi Therapeutics, Inc. (TVRD) (CIK 0001346830)
Date: April 2, 2019 · CIK: 0001346830 · Accession: 0001193125-19-095709
AI Filing Summary & Sentiment
File numbers found in text: 333-230333
Show Raw Text
CORRESP 1 filename1.htm CORRESP April 2, 2019 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Christine Westbrook Re: Cara Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-230333 Acceleration Request Requested Date: Thursday, April 4, 2019 Requested Time: 4:00 P.M. Eastern Daylight Time Dear Ms. Westbrook: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-230333) (the “Registration Statement”) to become effective on April 4, 2019, at 4:00 p.m. Eastern Daylight Time, or as soon thereafter as is practicable. Once the Registration Statement has been declared effective, please orally confirm that event with Darren DeStefano of Cooley LLP, counsel to the Registrant, at (703) 456-8034, or in his absence, Alison Haggerty at (212) 479-6596. Very truly yours, Cara Therapeutics, Inc. By: /s/ Scott Terrillion Scott Terrillion General Counsel, Secretary and Chief Compliance Officer cc: Derek Chalmers, Ph.D., D.Sc., Cara Therapeutics, Inc. Darren K. DeStefano, Cooley LLP Alison A. Haggerty, Cooley LLP